Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 220 (planned)
- Started
- Apr 15, 2025
- Main results expected
- Dec 6, 2027
- Fully finished
- Dec 6, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants who Experience a Dose-Limiting Toxicity (DLT)
Measured over: Day 1 to Day 21
Number of Participants who Experience an Adverse Event (AE)
Measured over: Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Parameters
Measured over: Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in Vital Signs
Measured over: Up to approximately 2 years
Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) Parameters
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06795412 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC